Martin pulled in compensation valued at nearly $180 million in 2013, including stock option gains worth $158 million, the biotech giant said Friday. Martin received $15.4 million in salary, incentive awards, stock and stock options - about what he's made in each of the past three fiscal years. But he cashed in on stock options for a $158.9 million gain and received another $4.8 million from shares that vested last year, Gilead said.
Martin's overall compensation was nearly double the $95.8 million he received in 2012, including $80.5 million from vested shares and stock option gains. He received about $54.5 million in 2011 compensation and $53.2 million in 2010, according to company filings.
Martin, who holds a doctorate in chemistry, has been Gilead's CEO since 1996.
Gilead says its executive compensation program is designed to "directly link pay with performance, creating appropriate incentives...that ultimately increase the value of Gilead and shareholder returns."
Moreover, prospects are bright for Sovaldi, a treatment for chronic hepatitis, whose annual sales could eventually hit $6 billion. Sovaldi received regulatory approval for a U.S. rollout in December.
Gilead has been a stellar Wall Street performer, with total shareholder return up 105% last year and 61% compounded annually since 2011.Still, at Friday's $75.05 close, shares are relatively flat this year and off 12% from a 52-week high.
Follow Strauss on twitter @gbstrauss.
No comments:
Post a Comment